Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

apatinib 3vistusertib 2olaparib 2camrelizumab 2atezolizumab 2Ipilimumab 2Everolimus 2trametinib 1toripalimab 1tilsotolimod 1tazemetostat 1tazarotene 1spartalizumab 1seviteronel 1sargramostim 1sacituzumab govitecan 1rucaparib 1roniciclib 1romiplostim 1pyrotinib 1phosphorylethanolamine 1pemigatinib 1pembrolizumab 1pazopanib 1palbociclib 1niraparib 1magrolimab 1lenvatinib 1irinotecan sucrosofate 1famitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumor × Everolimus × Clear all
NCT04185831 2024-08-22

MEGALiT

Uppsala University Hospital

Phase 2 Active not recruiting
167 enrolled
Other solid neoplasm

Solid Tumor

NCT02449538 2017-02-17

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Samsung Medical Center

Phase 2 Completed
10 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡